In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin, published in 2001-11-30, which mentions a compound: 89396-94-1, Name is (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, Molecular C20H28ClN3O6, Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride.
The hypothesis that angiotensin-converting enzyme (ACE) inhibitors interfere with the treatment of anemia with recombinant human erythropoietin (rHuEPO) remains controversial. To test this hypothesis, a retrospective anal. was conducted in a large group of hemodialysis patients with renal anemia. The effects of ACE inhibitors in these patients were evaluated by measuring the weekly increment in hematocrit (ΔHct) values within 12 wk of the initiation of rHuEPO treatment. Results from 2213 rHuEPO naive patients were compared between patients receiving rHuEPO alone and patients receiving both rHuEPO and ACE inhibitors. Because of the demog. differences between the two groups, a propensity score was used to eliminate the influence of confounding factors and to match the patient population in these two patient groups. Multiple regression anal. also was performed. When the ΔHct values were compared directly between the two groups or were assessed by multiple regression anal., no effect of ACE inhibitors was observed (P = 0.941 and P = 0.308, resp.). When the effects of ACE inhibitors on the treatment of anemia with rHuEPO were analyzed in 329 patients extracted from each group by their propensity score, ΔHct did not differ between the two groups (P = 0.355). These results suggest that ACE inhibitors have no effect on the rHuEPO treatment for anemia in hemodialysis patients who were treated with a relatively low dose of ACE inhibitors and low-dose rHuEPO.
From this literature《Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin》,we know some information about this compound(89396-94-1)Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, but this is not all information, there are many literatures related to this compound(89396-94-1).
Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”